MedTrace Logo

Expanded Access Program of Surufatinib

NCT04814732 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-04-12

No results posted yet for this study

Summary

This treatment protocol is intended to provide early access of surufatinib to patients with locally advanced or metastatic NETs for whom, in the opinion of their treating physician, other treatment options or surufatinib clinical trials in this indication are unsuitable. This EAP is currently available in the US only.

Conditions

Interventions

DRUG

Surufatinib

HMP-012

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Principal Investigators

  • Marjo Hahka-Kemppinen, MD · Hutchison Medipharma Limited

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04814732 on ClinicalTrials.gov